Association for Research in Vision and Ophthalmology

Association for Research in Vision and Ophthalmology

May 01, 2019
1 min watch
Save

VIDEO: 36-month Yutiq data released

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

VANCOUVER, British Columbia — EyePoint Pharmaceuticals CEO Nancy Lurker discusses 36-month safety and efficacy data for Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg), released at the Association for Research in Vision and Ophthalmology meeting here.

The uveitis recurrence rate was 56.3% in Yutiq-treated eyes compared with 92.9% in sham-treated eyes. Eyes treated with Yutiq needed adjunctive intraocular or periocular medications 19.5% of the time, whereas 69% of sham-treated eyes needed rescue.

 

Disclosure: Lurker reports she is CEO of EyePoint Pharmaceuticals.